The Valley Desk

NCT05119855 · Interventional trial

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Overall registry status Completed

Phase 3

Conditions Coronavirus Disease (COVID-19), Papillomavirus Infections

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov